COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

10.1101/2020.02.07.937862

10.5582/bst.2020.01020

10.1038/s41467-019-13940-6

10.1016/j.drudis.2020.01.015

10.1038/nrmicro3143

10.3389/fmicb.2017.01469

10.3389/fimmu.2018.01803

10.1080/01652176.2019.1580827

10.1038/nature02463

10.1136/thorax.2003.012658

10.1517/13543776.2013.823159

10.3390/v12010125

10.1038/d41586-020-00190-6

10.1080/01652176.2020.1727993

10.2478/acph-2020-0024

WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected; 2020. [accessed 2020 Feb 15]. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected

10.3760/cma.j..1001-0939.2020.0002

10.3201/1107.050219

10.1038/nrmicro2090

10.1002/jmv.25682

10.1080/22221751.2019.1597644

10.1016/j.virusres.2019.197834

10.1073/pnas.0403492101

10.1371/journal.pone.0220196

10.1016/j.antiviral.2016.11.006

10.1080/22221751.2020.1723441

10.1016/j.micinf.2020.01.003

10.1002/cbic.202000047

10.12688/f1000research.22149.1

10.1002/jmv.25698

10.1371/journal.pone.0144475

10.1109/TCBB.2017.2702588

10.1016/j.jinf.2005.04.010

10.1002/jmv.25707

NIAID. Developing therapeutics and vaccines for coronaviruses; 2020. [accessed 2020 Feb 15]. https://www.niaid.nih.gov/diseases-conditions/coronaviruses-therapeutics-vaccines

CEPI. CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019; 2020. [accessed 2020 Feb 15]. https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/

Moderna. Moderna announces funding award from CEPI to accelerate development of messenger RNA (mRNA) vaccine against novel coronavirus; 2020. [accessed 2020 Feb 15]. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-funding-award-cepi-accelerate-development

10.1016/j.virusres.2020.197863

10.1007/s11427-017-9189-3

10.1126/science.367.6477.492

10.1038/s41426-018-0031-3

10.1016/j.coviro.2015.06.009

10.3389/fmicb.2019.01781

10.1038/425915a

10.1016/j.vaccine.2006.07.009

10.1128/JVI.00304-08

10.1016/j.virusres.2007.03.025

10.1073/pnas.1323279111

10.1586/14760584.2016.1167603

10.1016/bs.aivir.2016.08.003

Yang XH, 2007, Comp Med, 57, 450

10.1056/NEJMc1215691

10.1371/journal.ppat.1004250

10.1128/JVI.00710-18

10.1080/14760584.2018.1506702

10.1038/nmicrobiol.2016.226

10.1007/978-1-0716-0211-9_12

10.3201/eid2002.131182

10.1128/JVI.78.12.6134-6142.2004

10.1128/JVI.01933-17

10.1128/JVI.78.19.10628-10635.2004

10.1002/jmv.20732

10.1038/s41422-020-0282-0

10.1016/j.antiviral.2013.11.004

10.1080/22221751.2019.1624482

10.1016/j.vaccine.2004.07.031

10.1128/JVI.80.8.4079-4087.2006

10.1128/JVI.00998-13

10.1038/nm.3362

10.1016/j.micinf.2013.06.003

10.1038/d41573-020-00016-0

10.3760/cma.j..1001-0939.2020.0014

10.1038/nrd.2015.37

10.1093/infdis/jiv392

10.1186/s13063-017-2427-0

10.1016/S0140-6736(20)30185-9

10.1016/j.jhin.2020.01.010